12 февр. 2024 г. · Novo Nordisk announced its acquisition of three fill-finish sites from Novo Holdings for $11 billion, subject to the closing of Novo ...

5 февр. 2024 г. · An independent financial advisor to Novo Nordisk, Evercore, has provided a fairness opinion to the Board of Directors, concluding that the ...

Advising Novo Nordisk on its acquisition of three fill-finish sites from Novo Holdings following its acquisition of Catalent. $11,000. February 5, 2024. Closed.

At Evercore, among other transactions, Mr. Maisonrouge was involved in advising Novo Nordisk in its acquisition of manufacturing facilities from Catalent; ...

26 апр. 2024 г. · ... Novo Nordisk and its shareholders. An independent financial advisor to Novo Nordisk, Evercore, has provided a fairness opinion to the Board of.

9 февр. 2024 г. · Novo Holdings agrees to acquire CDMO Catalent; sells three sites to subsidiary Novo Nordisk for Wegovy and Ozempic manufacturing capacity.

Notable deals include advising on Novo Nordisk's acquisitions of Dicerna Pharmaceuticals and Emisphere Technologies; Sanofi's acquisition of Principia ...

5 февр. 2024 г. · Evercore, Novo Nordisk's independent financial advisor, has also presented the Board of Directors with a fair judgment, stating that the ...

24 февр. 2024 г. · Novo Holdings, the entity with majority voting rights in Novo Nordisk, acquired US drug manufacturer Catalent for $16.5 billion.

1 нояб. 2024 г. · In the phase 3 Essence trial, a once-weekly dose of semaglutide 2.4 mg helped to improve liver fibrosis with no worsening of steatohepatitis.